Revenue segments as reported by the company.

Premiums

Product revenue

Administrative fees and other revenue

Net investment income

Net gains on financial instruments

Gain on sale of business

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit expense

Selling, general and administrative

Interest expense

Amortization of other intangible assets

Loss on extinguishment of debt

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Elevance Health Inc

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. The firm supports consumers, families, and communities across the entire care journey, connecting them to the care, support, and resources they need to lead healthier lives. It offers health plans and clinical, behavioral, pharmacy, and complex-care solutions which promote whole health. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elevance Health reports robust Q4 earnings, eyes margin optimization

Elevance Health's strong Q4 2022 performance, strategic acquisitions, and focus on margin optimization position the company for continued growth. With a clear outlook for 2023, emphasizing membership expansion and margin recovery, the company is poised for success. Challenges in optimizing margins and managing cost structures are balanced by growth opportunities and strategic initiatives.

Elevance Health reports robust Q1 growth and innovation in healthcare

Elevance Health Inc demonstrated strong financial performance and growth in Q1 2023, driven by increased membership and solid operating results.
The company's focus on advocacy, innovation, and sustainability, along with strategic investments in healthcare capabilities, positions it for continued success.
While facing challenges in cost management and strategic partnerships, Elevance Health is well-positioned to capitalize on opportunities in specialty care and value-based models.
Overall, Elevance Health's commitment to whole health, innovation, and value-based care sets a positive trajectory for future growth and industry leadership.

Elevance Health Inc posts robust Q2 earnings, eyes value-based care

Elevance Health Inc reported strong Q2 earnings, raised adjusted EPS outlook to over $32.85 for the year, and emphasized a focus on value-based care and digital solutions. While facing margin pressure in Carelon, the company remains confident in its strategy execution and performance for 2023 and beyond.

Elevance Health excels in Q3, eyes growth through strategic actions

Elevance Health's Q3 performance was strong, with a focus on operational efficiency and strategic investments. Challenges in Medicare ratings were addressed through proactive measures, while opportunities lie in growth acceleration and strategic partnerships. The company remains on track to achieve its long-term growth targets.

Elevance Health Inc surpasses earnings expectations, eyes growth opportunities

Elevance Health Inc's strong financial performance in Q4 2023 and full-year results, coupled with strategic initiatives in expanding capabilities and enhancing operational efficiency, position the company for continued success. Challenges in commercial repricing and Medicaid dynamics are being addressed, while opportunities in Medicare Advantage and strategic investments offer avenues for growth.

Elevance Health posts robust Q1 earnings, eyes strategic growth

Elevance Health demonstrated strong financial performance in Q1, with revenue growth and margin expansion in key segments.
While facing challenges like potential Medicare rate cuts, the company is leveraging partnerships and acquisitions for growth.
Opportunities lie in expanding service offerings, geographic footprint, and optimizing Medicaid margins for long-term sustainability.

Elevance Health Inc reports robust earnings growth and strategic wins

Elevance Health's Q2 performance reflects strong earnings growth and reaffirmed guidance, driven by solid segment performance and new business wins.
The company's strengths lie in its high Medicare rating, robust revenue growth in services, and strategic focus on value creation.
Challenges include sustaining growth momentum, managing funding cuts, and effectively integrating recent acquisitions for long-term success.
Opportunities exist in accelerating capabilities, expanding market share, optimizing operations, and leveraging workplace recognition for talent attraction and innovation.

Elevance Health faces Medicaid challenges, sees growth in AI investments

Elevance Health's Q3 earnings were impacted by elevated medical costs in Medicaid, leading to a reduction in full-year outlook. Despite challenges in the Medicaid business, the company's Medicare Advantage and Commercial businesses are performing well. Investments in AI and expansion of Carelon Services present growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Commercial and Specialty Business, Government Business, CarelonRx, and Other. The Commercial and Specialty Business segment provides insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance. The Government Business segment includes medicare and medicaid businesses, national government services, and services provided to the federal government. The CerelonRx segment offers formulary management, pharmacy networks, prescription drug database, member services, and mail order capabilities. The Other segment is involved in health services business focused on quality of healthcare by enabling and creating new care delivery and payment models. The company was founded in 1944 and is headquartered in Indianapolis, IN.

INDIANAPOLIS--(BUSINESS WIRE)---- $ELV #earnings--Elevance Health, Inc. (NYSE: ELV) reported fourth quarter and full year 2023 results. “We are pleased to have delivered another year of strong performance in 2023, enabled by our relentless focus on customer experience and affordability, and continued investments in growth and innovation. The balance and resilience of our business coupled with the focused execution of our enterprise strategy supports our confidence in our outlook for 2024, as we continue to optimi.

Elevance Health Reports Results for Fourth Quarter and Full Year 2023; Sets Full Year 2024 Outlook

Get a deeper insight into the potential performance of Elevance Health (ELV) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Countdown to Elevance Health (ELV) Q4 Earnings: Wall Street Forecasts for Key Metrics

Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums and product revenues.

Can Higher Costs Affect Elevance Health's (ELV) Q4 Earnings?

HealthEquity

Investors with an interest in Medical Services stocks have likely encountered both Elevance Health (ELV) and HealthEquity (HQY). But which of these two companies is the best option for those looking for undervalued stocks?

ELV or HQY: Which Is the Better Value Stock Right Now?

Here is how Elevance Health (ELV) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?

Elevance's (ELV) Carelon unit is expected to benefit from improving performance in the Behavioral Health business and post-acute care services.

Why You Should Retain Elevance (ELV) Stock in Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Elevance Health (ELV) is a Top Momentum Stock for the Long-Term

In the closing of the recent trading day, Elevance Health (ELV) stood at $475.12, denoting a -1.49% change from the preceding trading day.

Elevance Health (ELV) Stock Drops Despite Market Gains: Important Facts to Note

Elevance Health (ELV) launches a new program with an Affordable Connectivity Program offering free smartphones to eligible members.

Elevance Health (ELV) & Verizon Partner to Bring Health Equity

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) will release fourth quarter and full year 2023 financial results on January 24, 2024 at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 Access Code - 3972058 (Domestic) 312-470-0178 Access Code - 3972058 (Internati.

Elevance Health to Hold Conference Call and Webcast to Discuss Fourth Quarter Results on January 24, 2024

LAS VEGAS--(BUSINESS WIRE)--Elevance Health announced at the Consumer Electronics Show 2024 that it will launch a first-of-its-kind program that will offer high-quality smartphones with unlimited data, talk, and texting service at no cost to eligible individuals enrolled in some of its affiliated Medicaid health plans. These devices will be preloaded with a customized experience and give individuals access to digital and virtual healthcare tools that they might otherwise not have had. “Increase.

Elevance Health Addresses Healthcare's Digital Divide by Increasing Access to High-Quality Smartphones and Health-Related Digital Services

Cigna

Humana

Incyte

Insulet

UnitedHealth Group

Health Care Select Sector SPDR Fund

Zoetis

Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.

Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024

Archer-Daniels-Midland Company

Aflac

Cummins

Corteva Inc

CVS Health

Dominion Energy

Deere & Company

Discover

Dow Inc

eBay

Con Ed

Emerson Electric

Eaton

Fortune Brands Innovations Inc

FirstEnergy

W.W. Grainger

Intel

Johnson & Johnson

Nordstrom

Jackson Financial

KeyCorp

Kraft Heinz

In December, we (my wife and I) received a dividend income total of $10,193.04. Crossed the $10k threshold, again. Vanguard's High Dividend Yield ETF, which we have been buying for 3.5 years, literally has paid immense dividends.

Dividend Income Summary: Lanny's December 2023 Summary

Paragon doubles revenues and increases the number of infusion centers by 400% during Peak Rock's ownership AUSTIN, Texas, Jan. 5, 2024 /PRNewswire/ -- An affiliate of Peak Rock Capital ("Peak Rock"), a leading middle-market private investment firm, announced today it has signed a definitive agreement for the sale of Paragon Healthcare, Inc. ("Paragon" or the "Company") to Elevance Health (NYSE: ELV). Paragon is a leading provider of ambulatory and home infusion services as well as specialty pharmacy services.

PEAK ROCK CAPITAL AFFILIATE SELLS PARAGON HEALTHCARE, INC. TO ELEVANCE HEALTH

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) today announced that it has entered into an agreement to acquire Paragon Healthcare, Inc., a company specializing in life-saving and life-giving infusible and injectable therapies. For more than 20 years, Paragon Healthcare has provided infusion services to patients through its omnichannel model of ambulatory infusion centers, home infusion pharmacies, and other specialty pharmacy services. The company, headquartered in Plano, Texas, pr.

Elevance Health to Acquire Paragon Healthcare

Microsoft

If you're looking for the best dividend stocks to buy now, the WisdomTree U.S. Quality Dividend Growth Fund (NASDAQ: DGRW ) is an excellent place to start. DRGW is one of the largest U.S.-listed dividend growth ETFs with $9.2 billion in net assets.

The 3 Best Dividend Stocks to Buy Now

Medpace Holdings

Here are the three stocks, MEDP, ELV and HQY, which have the potential to shield your portfolio from the impact of healthcare staffing challenges in 2024.

3 Amazing Health Service Stocks to Brave "Labordemic" in 2024

Elevance Health (ELV) concluded the recent trading session at $465.78, signifying a -0.76% move from its prior day's close.

Elevance Health (ELV) Stock Falls Amid Market Uptick: What Investors Need to Know

Healthcare Services Group

Elevance Health Inc (NYSE: ELV) and Health Care Services Corp (NASDAQ: HCSG) are reportedly interested in buying the Medicare Advantage unit of Cigna Group (NYSE: CI). Here's what we know so far The said business is worth over $3.0 billion, as per a Bloomberg report on Friday.

Elevance, HCSC interested in Cigna's Medicare Advantage unit

Elevance's (ELV) Carelon unit will see growth due to improving performance in post-acute care services and Behavioral Health business.

Here's Why Investors Should Hold Elevance (ELV) Stock for Now

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, Inc. (NYSE: ELV) recently received the new Health Equity Accreditation Plus for 21 of its affiliated Medicaid plans from the National Committee for Quality Assurance (NCQA), a recognition that the company leads the industry in developing solutions to ensure access to high quality, equitable healthcare. Of the 28 organizations to receive this accreditation, Elevance Health Medicaid plans earned more than any other managed care organization. “Health.

Twenty-One Elevance Health Medicaid Plans Receive NCQA Health Equity Accreditation Plus

In the latest trading session, Elevance Health (ELV) closed at $488.06, marking a +0.94% move from the previous day.

Elevance Health (ELV) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Elevance Health (ELV) closed the most recent trading day at $476.96, moving -0.28% from the previous trading session.

Elevance Health (ELV) Stock Slides as Market Rises: Facts to Know Before You Trade

Elevance Health is launching a new digital pharmacy that allows health plan enrollees to engage more with pharmacists and track their prescriptions like Americans track a pizza delivery.

Elevance Health's PBM Launches 24/7 Digital Pharmacy

Elevance Health (ELV) concluded the recent trading session at $483.12, signifying a +0.76% move from its prior day's close.

News for Elevance Health Inc Stock (ELV)